Device Authority targets a core security gap in healthcare

Tern plc

Legacy medical devices are not disappearing from healthcare networks. Many hospitals still depend on older equipment that remains clinically useful, expensive to replace and difficult to take offline. That reality creates a clear security challenge: connected medical devices need to be protected even when they were not designed for today’s cybersecurity demands.

Device Authority argues that healthcare organisations need an identity-first security strategy to manage this risk. It is not enough to know that a device is connected to a network. Healthcare providers need to know what the device is, whether it can be trusted, whether its credentials are valid and whether it should be allowed to communicate with other systems.

Many legacy medical devices were built before modern security standards became common. Some may lack strong authentication. Others may rely on outdated software, limited update options or weak certificate management. In a hospital setting, these weaknesses can be difficult to fix quickly because the devices may support critical services and cannot always be replaced or patched without affecting clinical operations.

An identity-first approach puts the device itself at the centre of the security model. Each device needs a trusted identity that can be issued, managed, renewed and revoked across its lifecycle. This makes it easier to control access, reduce exposure and support compliance without depending only on network-based defences. It also gives healthcare organisations a more practical way to manage risk across mixed estates of new and old devices.

For Device Authority, the message is commercially relevant. Healthcare is a sector where connected-device security is not optional, but replacement cycles are long and operational disruption carries real consequences.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Search